Neuren Pharmaceuticals revises DAYBUE revenue projections to reach US$700 million in 2028

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus following the release of new guidance, with DAYBUE global net sales now projected to reach around US$700 million in 2028. The company highlighted that these royalties and milestone payments are currently Neuren’s only source of product revenue.

What did Neuren Pharmaceuticals report?

• DAYBUE global net sales projected to reach approximately US$700 million in 2028
• 2025 guidance for DAYBUE net sales remains at US$385–400 million
• Estimated Neuren royalties for 2025 are between A$63 million and A$66 million
• Exclusive worldwide licence granted to Acadia Pharmaceuticals for DAYBUE commercialisation
• International expansion anticipated, pending European approval (decision expected Q1 2026)

What else do investors need to know?

Neuren receives all its current product revenue from Acadia’s DAYBUE, with royalties and milestone payments tied directly to DAYBUE’s net sales. Acadia’s projections assume continued growth, including a rollout of DAYBUE STIX (approved in December 2025) and expansion into new markets if regulatory approvals are secured.

The latest forecast reflects stronger anticipated patient uptake and benefits from expanded US customer-facing teams. Investors should note that further guidance, including 2026 DAYBUE sales, is expected after Acadia’s Q4 results release in February.

What did Neuren Pharmaceuticals management say?

 Chief Financial Officer Ms Lauren Frazer said:

As noted above, royalties and milestone payments from ACAD are currently NEU’s sole source of product revenue. Those royalties and milestone payments are directly linked to the DAYBUE net sales achieved by ACAD. Given ACAD’s disclosed projection of DAYBUE net sales in 2028 reflects significant growth from its published guidance for net sales in 2025, NEU considers that the Information would have a material impact on NEU’s future revenue.

What’s next for Neuren Pharmaceuticals?

Neuren will continue to track DAYBUE’s performance and expects further clarity on European market entry in Q1 2026. The company remains focused on supporting Acadia’s international expansion plans and will provide updates as new sales projections or milestone triggers unfold.

Investors may want to keep an eye on regulatory milestones and subsequent guidance, as these could materially impact Neuren’s future royalty streams and the Neuren Pharmaceuticals share price.

Neuren Pharmaceuticals share price snapshot

Over the past 12 months, Neuren Pharmaceuticals shares have risen 48%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 7% over the same period. 

View Original Announcement

The post Neuren Pharmaceuticals revises DAYBUE revenue projections to reach US$700 million in 2028 appeared first on The Motley Fool Australia.

More reading

• This ASX stock just hit an all-time high. Is there more upside ahead?
• The best and worst ASX sectors of the past 12 months
• 5 things to watch on the ASX 200 on Monday
• ASX 200 materials sector outperforms as mining shares continue their ascent
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.